Peringatan Keamanan

Overdose

Overdosage has never been observed with sucralfate F4519. It is unlikely, as administering a maximum dose of up to 12 g/kg/body weight in several animal species did not result in death. The lethal dose could not be determined in these studies F4519. It is likely that overdose of sucralfate in humans would result in constipation, and supportive treatment would be advised F4519.

Use in pregnancy

This drug is considered a pregnancy Category B drug. Studies have been performed in rodents and rabbits at doses up to 50 times the recommended human dose. No harm to the fetus has been observed in the abovementioned studies. Sufficient and well-controlled clinical trials have not been performed in pregnant women. Due to the fact that the results of animal studies are not always relevant to human response, sucralfate should be used during pregnancy only if it is deemed essential for the mother's health FDA label.

Use in nursing

Whether this drug is excreted in human milk is currently unknown. Many drugs are excreted in breast milk, therefore, if sucralfate is administered to a lactating and nursing woman, caution should be observed FDA label.

Carcinogenesis

24 month toxicity studies were performed in rodents, and the dose of sucralfate reached up to 1 g/kg (equivalent to 12 times the recommended human dose). No signs of sucralfate-related tumors were notedFDA label.

Sucralfate

DB00364

small molecule approved

Deskripsi

Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers FDA label, gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia A177655. It is considered a cytoprotective agent, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances A177655, F4519.

Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form L6073, L6076.

Struktur Molekul 2D

Berat 1558.67
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half-life is not known. In animals, the elimination half-life of the sucrose component of this drug is from 6-20 h [F4537].
Volume Distribusi This drug is absorbed in a very small quantity, and normally localizes to inflamed gastrointestinal lesions [FDA label].
Klirens (Clearance) Sucralfate contains aluminum. The administration of sucralfate in non-dialyzed chronic renal failure patients warrants careful consideration from the treating physician as the excretion of absorbed aluminum may be decreased, causing possible aluminum toxicity [F4519]. In dialyzed patients diagnosed with chronic renal failure, aluminum toxicity related to sucralfate has been observed and reported. The daily amount of aluminum ingestion (including sucralfate) should be carefully examined before administering sucralfate in combination with other drugs also containing aluminum, including various antacids [F4519].

Absorpsi

This drug is absorbed from the gastrointestinal tract in very minimal quantities.FDA label The adsorbed sulfated disaccharide is excreted in the urine F4519. This drug contains aluminum and after the administration of 1 g of sucralfate 4 times per day, about 0.001% to 0.017% of this aluminum content is absorbed in patients with normal renal function.F4519 This number is expected to increase in those with impaired renal function.F4519

Metabolisme

This drug is absorbed in very small quantities and is not significantly metabolized FDA label, F4519.

Rute Eliminasi

The negligible amount of this drug that is absorbed is excreted mainly in the urine within 48 hours FDA label, F4537.

Interaksi Makanan

2 Data
  • 1. Take on an empty stomach. Take at least 1 hour before or 2 hours after meals.
  • 2. Take separate from antacids. Take at least 30 minutes before or after antacids.

Interaksi Obat

855 Data
Calcitriol The serum concentration of Sucralfate can be increased when it is combined with Calcitriol.
Calcifediol The serum concentration of Sucralfate can be increased when it is combined with Calcifediol.
Ergocalciferol The serum concentration of Sucralfate can be increased when it is combined with Ergocalciferol.
Cholecalciferol The serum concentration of Sucralfate can be increased when it is combined with Cholecalciferol.
Paricalcitol The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol.
Dihydrotachysterol The serum concentration of Sucralfate can be increased when it is combined with Dihydrotachysterol.
Alfacalcidol The serum concentration of Sucralfate can be increased when it is combined with Alfacalcidol.
Seocalcitol The serum concentration of Sucralfate can be increased when it is combined with Seocalcitol.
Inecalcitol The serum concentration of Sucralfate can be increased when it is combined with Inecalcitol.
Becocalcidiol The serum concentration of Sucralfate can be increased when it is combined with Becocalcidiol.
Eldecalcitol The serum concentration of Sucralfate can be increased when it is combined with Eldecalcitol.
1alpha,24S-Dihydroxyvitamin D2 The serum concentration of Sucralfate can be increased when it is combined with 1alpha,24S-Dihydroxyvitamin D2.
Elocalcitol The serum concentration of Sucralfate can be increased when it is combined with Elocalcitol.
Maxacalcitol The serum concentration of Sucralfate can be increased when it is combined with Maxacalcitol.
Doxercalciferol The serum concentration of Sucralfate can be increased when it is combined with Doxercalciferol.
Vitamin D The serum concentration of Sucralfate can be increased when it is combined with Vitamin D.
1alpha-Hydroxyvitamin D5 The serum concentration of Sucralfate can be increased when it is combined with 1alpha-Hydroxyvitamin D5.
Previtamin D(3) The serum concentration of Sucralfate can be increased when it is combined with Previtamin D(3).
Moxifloxacin Sucralfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Grepafloxacin Sucralfate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Enoxacin Sucralfate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pefloxacin Sucralfate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ciprofloxacin Sucralfate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Trovafloxacin Sucralfate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nalidixic acid Sucralfate can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rosoxacin Sucralfate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cinoxacin Sucralfate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lomefloxacin Sucralfate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gatifloxacin Sucralfate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Norfloxacin Sucralfate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levofloxacin Sucralfate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gemifloxacin Sucralfate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ofloxacin Sucralfate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sparfloxacin Sucralfate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Temafloxacin Sucralfate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fleroxacin Sucralfate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Technetium Tc-99m ciprofloxacin Sucralfate can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Garenoxacin Sucralfate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nemonoxacin Sucralfate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Flumequine Sucralfate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Enrofloxacin Sucralfate can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Orbifloxacin Sucralfate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sarafloxacin Sucralfate can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Difloxacin Sucralfate can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pazufloxacin Sucralfate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Prulifloxacin Sucralfate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Delafloxacin Sucralfate can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sitafloxacin Sucralfate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxolinic acid Sucralfate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rufloxacin Sucralfate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pipemidic acid Sucralfate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Doxycycline Sucralfate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lymecycline Sucralfate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Clomocycline Sucralfate can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxytetracycline Sucralfate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Demeclocycline Sucralfate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tetracycline Sucralfate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Metacycline Sucralfate can cause a decrease in the absorption of Metacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Minocycline Sucralfate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sarecycline Sucralfate can cause a decrease in the absorption of Sarecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Omadacycline Sucralfate can cause a decrease in the absorption of Omadacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Penimepicycline Sucralfate can cause a decrease in the absorption of Penimepicycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholic Acid Sucralfate can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Digoxin Sucralfate can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetyldigoxin Sucralfate can cause a decrease in the absorption of Acetyldigoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Metildigoxin Sucralfate can cause a decrease in the absorption of Metildigoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Furosemide Sucralfate can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levothyroxine Sucralfate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Quinine Sucralfate can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sulpiride Sucralfate can cause a decrease in the absorption of Sulpiride resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fluconazole Sucralfate can cause a decrease in the absorption of Fluconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Voriconazole Sucralfate can cause a decrease in the absorption of Voriconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Miconazole Sucralfate can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Itraconazole Sucralfate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Posaconazole Sucralfate can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Abafungin Sucralfate can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ravuconazole Sucralfate can cause a decrease in the absorption of Ravuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Isavuconazonium Sucralfate can cause a decrease in the absorption of Isavuconazonium resulting in a reduced serum concentration and potentially a decrease in efficacy.
Albaconazole Sucralfate can cause a decrease in the absorption of Albaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bifonazole Sucralfate can cause a decrease in the absorption of Bifonazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Isavuconazole Sucralfate can cause a decrease in the absorption of Isavuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levoketoconazole Sucralfate can cause a decrease in the absorption of Levoketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Eltrombopag Sucralfate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy.
Raltegravir Sucralfate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dicoumarol The therapeutic efficacy of Dicoumarol can be decreased when used in combination with Sucralfate.
Phenindione The therapeutic efficacy of Phenindione can be decreased when used in combination with Sucralfate.
Warfarin The therapeutic efficacy of Warfarin can be decreased when used in combination with Sucralfate.
Phenprocoumon The therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Sucralfate.
Acenocoumarol The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Sucralfate.
4-hydroxycoumarin The therapeutic efficacy of 4-hydroxycoumarin can be decreased when used in combination with Sucralfate.
Coumarin The therapeutic efficacy of Coumarin can be decreased when used in combination with Sucralfate.
(R)-warfarin The therapeutic efficacy of (R)-warfarin can be decreased when used in combination with Sucralfate.
Ethyl biscoumacetate The therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Sucralfate.
Fluindione The therapeutic efficacy of Fluindione can be decreased when used in combination with Sucralfate.
Clorindione The therapeutic efficacy of Clorindione can be decreased when used in combination with Sucralfate.
Diphenadione The therapeutic efficacy of Diphenadione can be decreased when used in combination with Sucralfate.
Tioclomarol The therapeutic efficacy of Tioclomarol can be decreased when used in combination with Sucralfate.
(S)-Warfarin The therapeutic efficacy of (S)-Warfarin can be decreased when used in combination with Sucralfate.
Deferasirox Sucralfate can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dolutegravir The serum concentration of Dolutegravir can be decreased when it is combined with Sucralfate.

Target Protein

Pepsin A-5 PGA5
Fibroblast growth factor 2 FGF2
Pro-epidermal growth factor EGF
Fibrinogen FGA

Referensi & Sumber

Synthesis reference: Nick V. Lazaridis, Moo K. Park, Yousry Sayed, "Method for preparing high potency sucralfate." U.S. Patent US4990610, issued March, 1973.
Artikel (PubMed)
  • PMID: 1715673
    Rees WD: Mechanisms of gastroduodenal protection by sucralfate. Am J Med. 1991 Aug 8;91(2A):58S-63S.
  • PMID: 11019606
    Candelli M, Carloni E, Armuzzi A, Cammarota G, Ojetti V, Pignataro G, Santoliquido A, Pola R, Pola E, Gasbarrini G, Gasbarrini A: Role of sucralfate in gastrointestinal diseases. Panminerva Med. 2000 Mar;42(1):55-9.
  • PMID: 2190306
    Lam SK: Why do ulcers heal with sucralfate? Scand J Gastroenterol Suppl. 1990;173:6-16.
  • PMID: 22242022
    Bardhan KD, Strugala V, Dettmar PW: Reflux revisited: advancing the role of pepsin. Int J Otolaryngol. 2012;2012:646901. doi: 10.1155/2012/646901. Epub 2011 Nov 10.
  • PMID: 1957124
    Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12.
  • PMID: 7948825
    Korman MG, Bolin TD, Szabo S, Hunt RH, Marks IN, Glise H: Sucralfate: the Bangkok review. J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):412-5.
  • PMID: 6892775
    Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8.
  • PMID: 2612985
    Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP: Clot lysis by gastric juice: an in vitro study. Gut. 1989 Dec;30(12):1704-7.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 130 • International brands: 4
Produk
  • Apo-sucralfate - Tab 1g
    Tablet • 1 g • Oral • Canada • Generic • Approved
  • Carafate
    Suspension • 1 g/10mL • Oral • US • Approved
  • Carafate
    Suspension • 1 g/10mL • Oral • US • Approved
  • Carafate
    Suspension • 1 g/10mL • Oral • US • Approved
  • Carafate
    Tablet • 1 g/1 • Oral • US • Approved
  • Dom-sucralfate
    Tablet • 1000 mg • Oral • Canada • Generic • Approved
  • Nu-sucralfate - Tab 1gm
    Tablet • 1 g • Oral • Canada • Generic • Approved
  • PMS-sucralfate
    Tablet • 1 g • Oral • Canada • Generic • Approved
Menampilkan 8 dari 130 produk.
International Brands
  • Antepsin — Orion
  • Sucramal — Menarini
  • Sucraxol — Medifarma
  • Ulcogant — Merck

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul